Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.

Caraffini V, Geiger O, Rosenberger A, Hatzl S, Perfler B, Berg JL, Lim C, Strobl H, Kashofer K, Schauer S, Beham-Schmid C, Hoefler G, Geissler K, Quehenberger F, Kolch W, Athineos D, Blyth K, Wölfler A, Sill H, Zebisch A.

Haematologica. 2019 May 16. pii: haematol.2018.209650. doi: 10.3324/haematol.2018.209650. [Epub ahead of print]

2.

Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia.

Zebisch A, Wölfler A, Fried I, Wolf O, Lind K, Bodner C, Haller M, Drasche A, Pirkebner D, Matallanas D, Rath O, Blyth K, Delwel R, Taskesen E, Quehenberger F, Kolch W, Troppmair J, Sill H.

Leukemia. 2012 Aug;26(8):1842-9. doi: 10.1038/leu.2012.61. Epub 2012 Mar 5.

PMID:
22388727
4.

Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.

Chang YI, You X, Kong G, Ranheim EA, Wang J, Du J, Liu Y, Zhou Y, Ryu MJ, Zhang J.

Leukemia. 2015 Sep;29(9):1847-56. doi: 10.1038/leu.2015.85. Epub 2015 Mar 24.

5.

Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.

Takemura T, Nakamura S, Yokota D, Hirano I, Ono T, Shigeno K, Fujisawa S, Ohnishi K.

J Biol Chem. 2010 Feb 26;285(9):6585-94. doi: 10.1074/jbc.M109.075788. Epub 2009 Dec 22.

6.

Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.

Wang T, Li C, Xia C, Dong Y, Yang D, Geng Y, Cai J, Zhang J, Zhang X, Wang J.

Am J Transl Res. 2015 Oct 15;7(10):1963-73. eCollection 2015.

7.

Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse.

Shen SW, Dolnikov A, Passioura T, Millington M, Wotherspoon S, Rice A, MacKenzie KL, Symonds G.

Exp Hematol. 2004 Sep;32(9):852-60.

PMID:
15345287
8.

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Wang J, Kong G, Liu Y, Du J, Chang YI, Tey SR, Zhang X, Ranheim EA, Saba-El-Leil MK, Meloche S, Damnernsawad A, Zhang J, Zhang J.

Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17.

9.

Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.

Zebisch A, Haller M, Hiden K, Goebel T, Hoefler G, Troppmair J, Sill H.

Leukemia. 2009 Jun;23(6):1049-53. doi: 10.1038/leu.2009.68. Epub 2009 Apr 9.

PMID:
19357705
10.

Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.

Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW.

J Exp Med. 1998 Jun 1;187(11):1893-902.

11.

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.

Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, Fleming MD, Young KH, Pitot H, Zhang J.

Blood. 2010 Dec 23;116(26):5991-6002. doi: 10.1182/blood-2010-04-281527. Epub 2010 Oct 4.

12.

Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.

Zhang J, Ranheim EA, Du J, Liu Y, Wang J, Kong G, Zhang J.

J Biol Chem. 2015 Jul 31;290(31):19093-103. doi: 10.1074/jbc.M115.653154. Epub 2015 Jun 16.

13.

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.

Drexler HG.

Leukemia. 1996 Apr;10(4):588-99. Review.

PMID:
8618433
14.

Targeting RAS signaling pathways in juvenile myelomonocytic leukemia.

Flotho C, Kratz C, Niemeyer CM.

Curr Drug Targets. 2007 Jun;8(6):715-25. Review.

PMID:
17584027
15.

Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.

Wolf S, Rudolph C, Morgan M, Büsche G, Salguero G, Stripecke R, Schlegelberger B, Baum C, Modlich U.

Oncogene. 2013 Jun 20;32(25):3028-38. doi: 10.1038/onc.2012.329. Epub 2012 Jul 30.

PMID:
22847614
16.

Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Hatzl S, Geiger O, Kuepper MK, Caraffini V, Seime T, Furlan T, Nussbaumer E, Wieser R, Pichler M, Scheideler M, Nowek K, Jongen-Lavrencic M, Quehenberger F, Wölfler A, Troppmair J, Sill H, Zebisch A.

Cancer Res. 2016 Jun 15;76(12):3644-54. doi: 10.1158/0008-5472.CAN-15-3049. Epub 2016 Apr 15.

17.

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.

18.

Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.

Jin X, Qin T, Zhao M, Bailey N, Liu L, Yang K, Ng V, Higashimoto T, Coolon R, Ney G, Figueroa ME, Li Q.

Blood Adv. 2018 Jun 12;2(11):1259-1271. doi: 10.1182/bloodadvances.2018017400.

19.
20.

Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway.

Shin SY, Rath O, Choo SM, Fee F, McFerran B, Kolch W, Cho KH.

J Cell Sci. 2009 Feb 1;122(Pt 3):425-35. doi: 10.1242/jcs.036319.

Supplemental Content

Support Center